Notal Vision Monitoring Center

08/26/2026

Intriguing and thoughtful discussion on role home OCT based monitoring can play in management of wet-AMD, the leading cause of blindness in the developed world among older adults. Great insights by Dr. Christina Weng, Dr. Noam Rudnick and Dr. Christina Flaxel.

In this episode of The Retina TL;DR with Dr. Weng, host Christina Y...

08/13/2026

💉What happens between the office visits for a neovascular AMD patient on long-acting treatments? 💉

Here is what Home OCT shows us in case of 76 yr old male with a port delivery system (PDS) implant in the left eye. Quick resolution of intraretinal fluid after refill, complete absence of macular fluid for several months, followed by recurrence. The subsequent refill again results in full fluid resolution. First refill Feb 22, 2023; second refill Dec 01, 2023.

𝘏𝘰𝘭𝘦𝘬𝘢𝘮𝘱, 𝘕𝘢𝘯𝘤𝘺 𝘔., 𝘦𝘵 𝘢𝘭. "𝘗𝘳𝘰𝘴𝘱𝘦𝘤𝘵𝘪𝘷𝘦 𝘵𝘳𝘪𝘢𝘭 𝘰𝘧 𝘩𝘰𝘮𝘦 𝘰𝘱𝘵𝘪𝘤𝘢𝘭 𝘤𝘰𝘩𝘦𝘳𝘦𝘯𝘤𝘦 𝘵𝘰𝘮𝘰𝘨𝘳𝘢𝘱𝘩𝘺–𝘨𝘶𝘪𝘥𝘦𝘥 𝘮𝘢𝘯𝘢𝘨𝘦𝘮𝘦𝘯𝘵 𝘰𝘧 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦𝘥 𝘯𝘦𝘰𝘷𝘢𝘴𝘤𝘶𝘭𝘢𝘳 𝘢𝘨𝘦-𝘳𝘦𝘭𝘢𝘵𝘦𝘥 𝘮𝘢𝘤𝘶𝘭𝘢𝘳 𝘥𝘦𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴." 𝘙𝘦𝘵𝘪𝘯𝘢 (𝘗𝘩𝘪𝘭𝘢𝘥𝘦𝘭𝘱𝘩𝘪𝘢, 𝘗𝘢.) 44.10 (2024): 1714.

08/12/2026

Congratulations to Michael Grassi, MD, and the Grassi Retina team on a great ForeseeHome catch.

This patient was referred for monitoring in June 2025 and generated a ForeseeHome alert April 2026. Just two days later, the patient was seen by Dr. Grassi and diagnosed with wet AMD while vision remained excellent at 20/25-2.

Dr. Grassi’s clinical note recognized the value of ForeseeHome in helping bring the patient back for timely evaluation following the alert.

The Notal Vision Monitoring Center is proud to partner with Grassi Retina to support monitoring patients between visits.

07/29/2026

Healio’s coverage of Home OCT results presented at the American Society of Retina Specialists Annual Meeting. See the insightful findings presented by Prof. Anat Loewenstein.

Home OCT combined with an AI analysis helped in the early detection of retinal fluid in patients with age-related macular degeneration, according to a speaker.In her presentation at the American Society of Retina Specialists annual meeting, Anat Loewenstein, MD, MHA, of Tel Aviv Medical Center, said...

07/22/2026

The American Society of Retina Specialists Annual Meeting was an impressive gathering of people and ideas advancing retinal care for millions of patients worldwide. Congratulations to ASRS President Dr. Geoffrey Emerson, Program Chair Dr. Nina Berrocal, and the entire team on a successful meeting.
Dr. Anat Loewenstein presented results from her study evaluating longitudinal AI-based Home OCT data against annotations from expert graders. The discussion reflected growing interest in Home OCT monitoring, particularly as longer-acting treatments create a greater need to understand what is happening between office visits.

07/15/2026

Congratulations to Whitney Boling, MD, Taylor Kersey, COA and the Boling Vision Center team for catching a patient’s wet AMD conversion with ForeseeHome!

This patient was referred in October 2025 with 20/20 vision and alerted in March 2026. At a follow-up visit a few days later, Dr. Boling diagnosed wet AMD while the patient’s vision remained an excellent 20/25.

The patient's consistent participation in home monitoring helped identify a meaningful change between office visits, allowing for timely clinical evaluation while visual acuity was still good.

The Notal Vision Monitoring Center is proud to partner with Boling Vision Center to help identify wet AMD early enough for physicians to help patients maintain their functional vision.

06/30/2026

The future of retinal care isn't just about longer-lasting therapies, it's also about better data between office visits.

A newly published peer-reviewed study in Medicina MDPI demonstrates that Home OCT monitoring can serve as a safety net for patients with neovascular AMD receiving standard care.

Key findings:
• 65% of treatment intervals showed persistent or recurrent retinal fluid before the next scheduled office visit.
• Disease activity was detected an average of 32 days earlier than the next routine visit.
• Nearly 70% of these intervals had the potential for an earlier clinical evaluation within currently labeled treatment intervals.

For retina specialists, this means greater confidence that disease reactivation won't go unnoticed between visits.

For pharmaceutical innovators developing long-acting anti-VEGF therapies and gene therapies, it highlights an important opportunity: treatment durability delivers its greatest value when paired with continuous disease surveillance.

The publication further reinforces that the Home OCT monitoring program complements, not replaces, standard retinal care by providing physicians with objective structural retinal information between office visits, enabling timely clinical evaluation when disease activity returns.

As therapies become more durable, monitoring should become more continuous.

The publication adds to the growing body of evidence supporting Home OCT monitoring and should help advance payer coverage, ensuring that patients who can benefit from this technology have access to the care they need.

Read the paper: https://notalvision.info/4wheE8z

06/24/2026

Congratulations to David Dao, MD and the Elman Retina Group, P.A. team for catching a patient’s wet AMD conversion with ForeseeHome!

This patient was referred in June 2025 with 20/20 vision and was an excellent ForeseeHome tester. After a ForeseeHome alert in March 2026, the patient was seen by Dr. Dao the next day, diagnosed, and promptly treated while vision was still 20/30.

A textbook catch case like this reflects the value of consistent home monitoring, timely follow-up, and a care team ready to act when meaningful changes are identified.

The Notal Vision Monitoring Center is proud to partner with Elman Retina Group to support monitoring between visits and help catch wet AMD early enough to preserve functional vision.

06/16/2026

Another great Clinical Trials at the Summit is in the books!

Prof. Anat Loewenstein delivered an excellent presentation on the future of care for patients with neovascular AMD, including the arrival of long-acting treatments and the growing role of home OCT-based monitoring.

Her presentation also underscored how home OCT may support clinical trials for upcoming therapies by providing more frequent insight into disease activity between office visits.

Congratulations to meeting co-chairs Arshad Khanani, MD, MA, FASRS; Jeffrey Heier, MD; and Peter Kaiser, MD, along with the full organizing team, on an excellent meeting.

CTS Retina

06/10/2026

A great ForeseeHome catch by Henry Bausback, OD and The Eye Associates team.

Referred in April 2025, this patient tested consistently with ForeseeHome over the months that followed. In February 2026, a ForeseeHome alert led to a wet AMD diagnosis and prompt treatment while the patient’s vision was 20/25.

This case highlights the value of staying connected to patients between visits. With consistent monitoring over time, meaningful changes can be identified and acted on when follow-up is needed.

Congratulations to Dr. Bausback and The Eye Associates team on this important catch.

The Notal Vision Monitoring Center is proud to partner with The Eye Associates to support monitoring patients between visits.